IN8bio INAB Stock
IN8bio Price Chart
IN8bio INAB Financial and Trading Overview
| IN8bio stock price | 1.54 USD |
| Previous Close | 1.87 USD |
| Open | 1.84 USD |
| Bid | 1.31 USD x 200 |
| Ask | 2.18 USD x 200 |
| Day's Range | 1.72 - 1.86 USD |
| 52 Week Range | 1.17 - 4.17 USD |
| Volume | 92.24K USD |
| Avg. Volume | 68.78K USD |
| Market Cap | 16.59M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.54 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.25 USD |
INAB Valuation Measures
| Enterprise Value | -2551536 USD |
| Trailing P/E | N/A |
| Forward P/E | -1.6320755 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.7479464 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.143 |
Trading Information
IN8bio Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | -53.49% |
| S&P500 52-Week Change | 27.29% |
| 52 Week High | 4.17 USD |
| 52 Week Low | 1.17 USD |
| 50-Day Moving Average | 1.54 USD |
| 200-Day Moving Average | 1.88 USD |
INAB Share Statistics
| Avg. Volume (3 month) | 68.78K USD |
| Avg. Daily Volume (10-Days) | 83.93K USD |
| Shares Outstanding | 9.59M |
| Float | 7.03M |
| Short Ratio | 2.6 |
| % Held by Insiders | 20.78% |
| % Held by Institutions | 38.11% |
| Shares Short | 161.81K |
| Short % of Float | 1.83% |
| Short % of Shares Outstanding | 1.64% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:30 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -52.74% |
| Return on Equity (ttm) | -103.55% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -17839000 USD |
| Net Income Avi to Common (ttm) | -18980000 USD |
| Diluted EPS (ttm) | -2.54 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 21.94M USD |
| Total Cash Per Share (mrq) | 2.23 USD |
| Total Debt (mrq) | 2.35M USD |
| Total Debt/Equity (mrq) | 10.33 USD |
| Current Ratio (mrq) | 10.501 |
| Book Value Per Share (mrq) | 2.313 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -14537000 USD |
| Levered Free Cash Flow (ttm) | -7128875 USD |
Profile of IN8bio
| Country | United States |
| State | NY |
| City | New York |
| Address | 350 5th Avenue |
| ZIP | 10118 |
| Phone | 646 600 6438 |
| Website | https://in8bio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 17 |
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer; and INB-600, a gamma-Delta T cell engager. In addition, it is developing INB-619, a gamma-delta TCE targeting CD19 for potential applications in both oncology and autoimmune diseases. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Q&A For IN8bio Stock
What is a current INAB stock price?
IN8bio INAB stock price today per share is 1.54 USD.
How to purchase IN8bio stock?
You can buy INAB shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for IN8bio?
The stock symbol or ticker of IN8bio is INAB.
Which industry does the IN8bio company belong to?
The IN8bio industry is Biotechnology.
How many shares does IN8bio have in circulation?
The max supply of IN8bio shares is 9.59M.
What is IN8bio Price to Earnings Ratio (PE Ratio)?
IN8bio PE Ratio is now.
What was IN8bio earnings per share over the trailing 12 months (TTM)?
IN8bio EPS is -2.54 USD over the trailing 12 months.
Which sector does the IN8bio company belong to?
The IN8bio sector is Healthcare.
IN8bio INAB included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Global Market Composite NQGM | 2296 USD — |
-1.38
|
— — | 2280.64 USD — | 2323.09 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
- {{ link.label }} {{link}}